Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Deutsche Bank upgrades Watches of Switzerland to 'buy'

(Sharecast News) - Deutsche Bank upgraded Watches of Switzerland on Wednesday to 'buy' from 'hold', saying it was "time to put the risk in perspective". The bank said: "We believe the downside risk to WOSG earnings driven by US import tariffs is much more contained than the shares are reflecting.

"This is based on our view that where the real risk sits, demand for non supply constrained brands in the US, is a much smaller part of the gross profit pool than is perhaps appreciated."

DB said that on its estimates it's circa 12% of the gross profit pool this year, and this limits the downside risk.

"Even on a sharper downside scenario that sees these brands put through 15% pricing with volumes - 30% in FY27 and squeeze margins further, the shares are still trading on a circa 9x PE, versus the 11x our target price is predicated on."

Deutsche Bank kept its price target at 450p.

Earlier on Wednesday, the company said in an update that it does not expect any material impact from US tariffs in the first half of fiscal 2026 as brand partners increased inventories.

WOSG held full-year guidance despite US President Donald Trump slapping Switzerland with a shock 39% tariff on exports. It said trading had been consistently strong in the 18 weeks to August 31.

At 1050 BST, the shares were up 7% at 341.20p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.